Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time

Author(s):  Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott

Issue:  Mar/Apr 2015 - Volume 19, Number 2
View All Articles in Issue

Page(s):  167-173

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 1
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 2
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 3
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 4
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 5
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 6
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Page 7

Download in electronic PDF format for $75

Abstract:  Many patients with chronic neuropathic pain continue to suffer despite traditional pharmacotherapy. As a result, pharmacists commonly compound gabapentin into creams, gels, and ointments as an alternative treatment option. In this study, various concentrations (1%, 5%, and 10%) of topical gabapentin compounded in Lipoderm were applied at various pre-treatment times (30 minutes, 1 hour, and 4 hours) to investigate what gabapentin concentration and pre-treatment time best attenuates formalin-induced nociceptive behaviors in a rodent model. A 30-minute pre-treatment with 5% gabapentin demonstrated maximum attenuation of nociceptive behaviors in this in vivo preclinical pain model. Nociceptive behaviors unexpectedly increased when gabapentin concentration or pre-treatment time was increased, suggesting both antinociceptive and pronociceptive effects of transdermal gabapentin administration. Gabapentin permeation into the skin and deeper tissues of the hindpaw was measured following the in vivo study. Skin and deep tissue permeation of gabapentin was both dose and time-dependent. Maximum deep tissue permeation occurred within 30 minutes of topical application. Skin concentrations increased with a longer 1-hour pre-treatment. Minimal skin and deeper tissue levels were found following a 4-hour pre-treatment. These results suggest that topical gabapentin may be antinociceptive in a rodent formalin model at specific doses and pre-treatment intervals.

Related Keywords: Allie Heustess, Shuler Spigener, Sarah Sweitzer, PhD, Alfonso Romero-Sandoval, PhD, Scott Asbill, PhD, gabapentin, chronic pain, neuropathic pain, neuropathy, topical analgesics, topical preparation, transdermal delivery, skin permeation, transdermal penetration, formalin pain model, dose-dependent pain relief, analgesia, voltage-dependent calcium channel blocker, alpha-2-delta subunit inhibitor, pain-related behavior, antinociception

Related Categories: PAIN MANAGEMENT, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie
, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 167-173

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan
, Asbill Scott, Sweitzer Sarah
Nov/Dec 2014
Pg. 504-511

Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan
, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
Mar/Apr 2015
Pg. 161-166

Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model
Baneshi Marzieh
, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
Sep/Oct 2023
Pg. 424-430

Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh
, Baltzley Sarah, AlGhananeem Abeer
Nov/Dec 2018
Pg. 498-503

In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie
, Asbill Scott, Eagerton David, Arnold John
Nov/Dec 2014
Pg. 512-515

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah
, Agu Remigius U
Nov/Dec 2019
Pg. 496-503

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2024
Pg. 111-116

Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
Mar/Apr 2011
Pg. 157

Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
Mar/Apr 2024
Pg. 131

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Nov/Dec 2020
Pg. 446-448

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel
, Arnold John J, McKay Doug, Abill C Scott
May/Jun 2013
Pg. 247-253

Return to Top